Company Filing History:
Years Active: 2010-2018
Title: Eva Figueroa Navarro: Innovator in HSP90 Inhibition
Introduction
Eva Figueroa Navarro is a prominent inventor based in Cambridge, GB. She has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that inhibit HSP90, a crucial protein involved in cancer cell proliferation.
Latest Patents
Among her latest patents, Eva has developed hydroxybenzamide derivatives that serve as inhibitors of HSP90. These compounds are characterized by a specific formula that includes various functional groups, providing them with the ability to inhibit the activity of HSP90 effectively. The invention outlines compounds that can be utilized in therapeutic applications, showcasing their potential in cancer treatment.
Career Highlights
Eva Figueroa Navarro has been instrumental in advancing research at Astex Therapeutics Limited, where she has contributed to the development of innovative therapeutic solutions. Her work has led to the filing of ten patents, reflecting her dedication to innovation and her impact on the pharmaceutical industry.
Collaborations
Throughout her career, Eva has collaborated with notable colleagues, including Maria Grazia Carr and Gianni Chessari. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic agents.
Conclusion
Eva Figueroa Navarro stands out as a leading inventor in the field of HSP90 inhibition, with a strong portfolio of patents and impactful collaborations. Her work continues to pave the way for advancements in cancer treatment and medicinal chemistry.